1 / 18

New multifaceted approach to plaque stabilization

• Stabilization of destabilized (disrupted and/or thrombotic plaque) • Stabilization of vulnerable (prone to destabilization) plaque. • Stabilization through the following processes  Thrombogenicity in blood  Vessel passivation Traditional concepts of stabilization:

stesha
Download Presentation

New multifaceted approach to plaque stabilization

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. • Stabilization of destabilized (disrupted and/or thrombotic plaque) • Stabilization of vulnerable (prone to destabilization) plaque • Stabilization through the following processes Thrombogenicity in blood Vessel passivation Traditional concepts of stabilization:  Plaque lipid and thrombogenicity  Inflammation  Endothelial function • Stabilization to prevent – In-hospital events – Intermediate and long-term events VBWG New multifaceted approach to plaque stabilization Adapted from Ambrose JA, Martino EE. Circulation. 2002;105:2000-4.

  2. Statins LDL oxLDL Lymphocyte 3 1 NO Inactivation 2 LFA-1 Monocyte – NO Selective block – HMG-CoA reductase activity ICAM-1 – Reduced adhesion NO production Geranylgeranyl PP Farnesyl PP – + + Reduced prenylation Rho protein Increased stability of mRNA Increased transcription NOS mRNA Decreased activation NF-kB Endothelial cell VBWG Anti-inflammatory actions of statins LFA-1 = lymphocyte function-associated antigen-1 Sposito AC, Chapman J. ATVB. 2002;22:1524-34.

  3. VBWG “At this juncture, there is no clear evidence that clinicians should choose statins on the basis of CYP3A4 metabolism when clopidogrel coadministration is required.”

More Related